Interstitial pneumonia merger stage IV non-small cell lung cancer case with the malignant pleural effusion
Conditions
Interventions
Sponsors
National Hospital Organization Kinki -Chuo Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) cytologically or histologically proven non-small cell lung cancer 2) cytologically or histologically proven malignant pleural effusion ,which had been untreated 3) Non-treatment case for non-small cell lung cancer or systemic treatment had been administered at least 31 days more before entry 4) dyspnea prior to chest tube drainage 5)a full expansion of lung obtained by chest tube drainage 6) Eligible patients were aged between 20 and 80 years 7) Eastern Cooperative Oncology Group(ECOG)PS 0-2 8) intestinal lung disease examined by computed tomography.(Intestinal lung diseases involve IPF,NSIP,DIP,RB-ILD, collagen vascular disease with intestinal lung disease and asbestosis related intestinal lung disease. AIP and COP were excluded) 9)life expectancy >= 30days 10)Written informed consent were obtained from the patient 11)14 days before entry, the following laboratory values were required: a leukocyte count>= 3000mm^3 a platelet count >= 100000mm^3 alanine aminotransferase < 100IU/l asparate aminotransferase< 100IU/l a serum creatinine level<= 1.5mg/dl
Exclusion criteria
Exclusion criteria: Exclusion criteria were as follows 1) All 1-3 were found within 30 days or possibility of acute exacerbation of intestinal lung disease. 1. worsening of respiratory distress 2. emerging ground grass attenuation or consolidation of the lung by computed tomography 3. worsening of PaO2 >= 10Torr 2) lung cancer had not been treated within 30 days 3) active double cancer 4) allergic reaction for lidocaine 5) carcinomatous pericarditis 6) uncontrolled heart failure 7) myocardial infarction within 30days 8) unstable angina pectoris 9) active infectious diseases 10) drug allery>= Grade3 11) Pregnancy, lactating woman, women of childbearing potential and patients not intend to prevent pregnancy 12) allergic pulmonary disorders or acute exacerbation of intestinal lung diseases 13) surgical treatment had previously been done for thorax in the malignant effusion 14) steroid usage (predonine >= 5mg) 15) SpO2 <90(under room air) 16) physician assessed that patients are not adequate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The pleural effusion control rate (30days after administration of hypotonic cisplatin for malignant pleural effusion) | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of acute exacerbation of intestinal lung disease,overall survival, pleural effusion free progression free survival, Toxicities | — |
Countries
Japan
Contacts
Public ContactTakehiko Kobayashi
National Hospital Organization Kinki -Chuo Medical Center Medicine in general
Outcome results
None listed